Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-01-11 00:00:00 ET · period of report 2022-01-08 · accession 0001714899-22-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-11 | 2022-01-08 | DNLI | Thornberry Nancy | Dir | A - Grant | $0.00 | +627 | 2,511 | +33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-08 | A | A | 627 | $0.00 | 2,511 | D | — | — | (F1) The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 1884 previously reported restricted stock units and 627 shares acquired pursuant to vesting of restricted stock units. |